Market Overview

Incyte Downgraded As RBC Analyst Awaits More Revenue Visibility

Share:
Incyte Downgraded As RBC Analyst Awaits More Revenue Visibility
Related INCY
The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet
The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs
Stocks To Watch: Calling Up Animal Spirits (Seeking Alpha)

Incyte Corporation (NASDAQ: INCY) has suffered a series of setbacks in its clinical programs, with the company's epacadostat  failing to meet endpoints in a late-stage study for metastatic melanoma when evaluated in combination with Merck & Co., Inc. (NYSE: MRK)'s Keytruda.

Incyte is scrapping a study of its INCB50465 pipeline candidate for diffuse large-B cell lymphoma.

The Analyst

RBC Capital Markets analyst Brian Abrahams downgraded Incyte from Outperform to Sector Perform and lowered the price target from $76 to $74.

The Thesis

The Street overreacted to the recent clinical trial setbacks and shares should rebound to the mid-$70s, Abrahams said in a Tuesday note.

The price level accounts for the substantial opportunity presented by Jakafi, Incyte's lead product for myelofibrosis, through its out-year patient cliff and probability-adjusted pipeline prospects, the analyst said. 

"We remain positive on Jakafi's growth prospects in existing MF/PV indications, which we believe sets a solid foundation floor," Abrahams said. The analyst estimates long-term Jakafi sales of $3 billion for the current indications.

Incyte's pipeline is crucial in light of the recent setbacks, as investors begin to focus on out-year Jakafi patient cliffs, the analyst said. 

The company's focus on targeted oncology and immuno-onocology as well as rheumatology and inflammation is viewed with skepticism by RBC, given the crowded nature of the spaces.

" ... The company's impressive translational work and medicinal chemistry should help set [it] up well longer-term, but in the nearer term we would expect shares to trade in line until there is more visibility on meaningful new revenue opportunities," Abrahams said. 

The Price Action

Incyte shares were moving down 5.63 percent to $67.79 at the time of publication Tuesday.

Related Links:

Benzinga's Daily Biotech Pulse: Epidiolex, Roche's Influenza Drug Gets Priority Review Status, Xeris Jumps On Positive Trial Results

The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs

Latest Ratings for INCY

DateFirmActionFromTo
Aug 2018RBC CapitalUpgradesSector PerformOutperform
Aug 2018JMP SecuritiesDowngradesOutperformMarket Perform
Jul 2018OppenheimerMaintainsPerformPerform

View More Analyst Ratings for INCY
View the Latest Analyst Ratings

Posted-In: Brian Abrahams RBC Capital MarketsAnalyst Color Biotech Downgrades Price Target Analyst Ratings General Best of Benzinga

 

Related Articles (INCY + MRK)

View Comments and Join the Discussion!

SMC3: Blockchain Panelists Talk Current Use Cases, Regulation, And Crypto

Mid-Day Market Update: Crude Oil Up Over 1%; Achaogen Shares Plunge